Frontier sites in clinical trials: Opportunities, challenges, and models.

Andrea Bastek¹, Amanda Zenere¹, Heather Manley², Camille Finkle³, Chad Jaeger⁴, Janet Matthews⁵, Kristie Moffett⁶, Megan Solomon⁷, Paula Underhill⁸

¹Florence Healthcare, United States.

²Clinvest Headlands, United States.

³Nuvance Health, United States.

⁴Banner Research, United States.

⁵Drexel University, College of Medicine, United States.

⁶Moffitt Cancer Center, United States.

⁷Northwest Georgia Oncology Centers, P.C., United States.

⁸PPD Clinical Research Services, Thermo Fisher Scientific, United Kingdom.

PubMed PMC DOI PDF

Abstract

BACKGROUND: The clinical trials industry faces a growing capacity gap driven by an increasing number of studies combined with site and staff shortages. The Site Enablement League (SEL) Task Force on Frontier Sites was established to explore the potential of non-traditional research sites-termed "frontier sites"-to address these issues by expanding access to underserved populations and embedding cl…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.